Counting the days till Zyprexa's patent runs out

The Zyprexa countdown nears its end. As the Indianapolis Star reports, there are only 21 days remaining on the blockbuster antipsychotic's patent, meaning Eli Lilly will soon face copycat rivals to its biggest-selling medication ever. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.